Live oral typhoid vaccine Salmonella Typhi Ty21a-A surrogate vaccine against non-typhoid salmonella?

被引:29
|
作者
Kantele, Anu [1 ,2 ,3 ]
Pakkanen, Sari H. [1 ,2 ]
Siitonen, Anja [4 ]
Karttunen, Riitta [5 ]
Kantele, Jussi M. [6 ]
机构
[1] Helsinki Univ Hosp, Dept Med, Div Infect Dis, Helsinki 00029, Finland
[2] Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki 00014, Finland
[3] Univ Helsinki, Dept Med, Inst Clin Med, Helsinki, Finland
[4] Natl Inst Hlth & Welf THL, Dept Infect Dis Surveillance & Control, Bacteriol Unit, Helsinki 00271, Finland
[5] Helsinki Univ Hosp, Dept Virol & Immunol, Div Clin Microbiol, Helsinki 00029, Finland
[6] Univ Turku, Dept Med Microbiol & Immunol, FIN-20520 Turku, Finland
关键词
Salmonella Typhi Ty21a; Oral vaccine; Non-typhoid Salmonella; Cross-reactive; Antibody-secreting cell; Salmonella Enteritidis; ANTIBODY-SECRETING CELLS; ENTERICA SEROTYPE ENTERITIDIS; SEROVAR PARATYPHI; HOMING POTENTIALS; IMMUNE-RESPONSE; IGA; TYPHIMURIUM; CHALLENGE; GUT; INFECTIONS;
D O I
10.1016/j.vaccine.2012.10.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Non-typhoid Salmonella (NTS) is a leading cause of food-borne illness with more than 90 million annual cases and an emerging antimicrobial resistance among the strains worldwide. Paradoxically, no vaccines are available against these pathogens. Numerous NTS strains share surface O-antigens with Salmonella enterica serotype Typhi. As intestinal antibodies against O-antigens have proven protective against NTS in animal experiments, it appears conceivable that the oral whole-cell typhoid vaccine, Salmonella Typhi Ty21a (Vivoti (R)), which effectively elicits intestinal antibodies against O-antigens, could exhibit cross-protective efficacy against NTS. We sought immunological evidence in support of cross-protective efficacy of Ty21a against NTS. Materials and methods: 35 volunteers receiving Ty21a vaccine and five patients with enteric fever were investigated with ELISPOT for circulating plasmablasts secreting antibodies reactive with Salmonella Typhi and six different NTS serotypes. These plasmablasts were also analysed for homing receptor expressions. Results: In all vaccinees and patients, a strong gut-directed cross-reactive plasmablast response was found against serotypes sharing the two O-antigens with Salmonella Typhi (0-9,12) (in vaccinees, mean: 95%CI 268: 228-508 and 363: 234-493 plasmablasts/10(6)PBMC against Salmonella Typhi and Enteritidis). Responses against strains sharing one O-antigen (0-12) were weaker (222: 105-338 against Salmonella Typhimurium), while no significant reactivity was detected against strains without typhoidal O-antigens. Conclusions: Intestinal antibodies against O-antigens protect against NTS in animal experiments. Ty21a was found to elicit intestinal immune responses cross-reactive with NTS strains sharing O-antigens with Ty21a. These include the most common NTS, Salmonella Enteritidis and Typhimurium. The data suggest that Ty21a may have cross-protective efficacy against numerous NTS strains. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7238 / 7245
页数:8
相关论文
共 50 条
  • [1] EFFICACY OF LIVE ORAL TYPHOID VACCINE (SALMONELLA-TYPHI TY-21A) IN VOLUNTEER STUDIES AND FIELD TRIALS
    CRYZ, SJ
    FURER, E
    LEVINE, MM
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1988, 118 (13) : 467 - 470
  • [2] The rpoS mutant allele of Salmonella typhi Ty2 is identical to that of the live typhoid vaccine Ty21a
    Robbe-Saule, V
    Norel, F
    [J]. FEMS MICROBIOLOGY LETTERS, 1999, 170 (01) : 141 - 143
  • [3] ANTIBODY-RESPONSE TO THE PROTEIN ANTIGENS OF SALMONELLA-TYPHI DURING TYPHOID INFECTION AND FOLLOWING VACCINATION WITH A LIVE ORAL TYPHOID VACCINE TY21A
    CHAU, PY
    TSANG, RSW
    [J]. DEVELOPMENTS IN BIOLOGICALS, 1982, 53 : 29 - 31
  • [4] ATTENUATED TYPHOID VACCINE SALMONELLA-TYPHI TY21A - FINGERPRINTING AND DUALITY CONTROL
    MCKENNA, AJ
    BYGRAVES, JA
    MAIDEN, MCJ
    FEAVERS, IM
    [J]. MICROBIOLOGY-UK, 1995, 141 : 1993 - 2002
  • [5] A CONTROLLED FIELD TRIAL OF LIVE SALMONELLA-TYPHI STRAIN TY 21A ORAL VACCINE AGAINST TYPHOID - 3-YEAR RESULTS
    WAHDAN, MH
    SERIE, C
    CERISIER, Y
    SALLAM, S
    GERMANIER, R
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1982, 145 (03): : 292 - 295
  • [6] COMPLIANCE WITH LIVE, ORAL TY21A TYPHOID VACCINE
    KAPLAN, DT
    HILL, DR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (08): : 1074 - 1074
  • [7] PRECAUTIONS WITH ORAL LIVE TYPHOID (TY-21A) VACCINE
    WOLFE, MS
    [J]. LANCET, 1990, 336 (8715): : 631 - 632
  • [8] IMMUNOGENICITY OF THE LIVE ORAL TYPHOID VACCINE TY21A
    BARTHOLOMEUSZ, RCA
    JOHNSON, M
    LABROOY, JT
    SHEARMAN, DJC
    ROWLEY, D
    [J]. GASTROENTEROLOGY, 1985, 88 (05) : 1317 - 1317
  • [9] ISOLATION AND CHARACTERIZATION OF GAL-E MUTANT TY 21A OF SALMONELLA-TYPHI - CANDIDATE STRAIN FOR A LIVE, ORAL TYPHOID VACCINE
    GERMANIER, R
    FURER, E
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1975, 131 (05): : 553 - 558
  • [10] Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine
    Levine, MM
    Ferreccio, C
    Abrego, P
    San Martin, O
    Ortiz, E
    Cryz, S
    [J]. VACCINE, 1999, 17 : S22 - S27